Mechanistic studies revealed that 35 down-regulates eEF2K by promoting SCF βTrCP-mediated protein degradation and enhances the anticancer activity of cisplatin in HCC cells via apoptosis and autophagy [121]. Here, EEF2K is linked to hepatocellular carcinoma.